Compounds > bicalutamide

bicalutamide and sirolimus

bicalutamide has been researched along with sirolimus in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (20.00)29.6817
2010's8 (80.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Bedolla, RG; Ghosh, PM; Kreisberg, JI; Malik, SN; Mikhailova, M; Prihoda, TJ; Troyer, DA; Wang, Y1
Brodie, AM; Goloubeva, O; Njar, VC; Sabnis, G; Schayowitz, A1
Cheng, J; Chhipa, RR; Ip, C; Mohler, JL; Wu, Y; Zhang, H1
Clackson, T; Miller, D; Rivera, VM; Squillace, RM; Wang, F; Wardwell, SD1
Bubley, GJ; Buckle, G; Courtney, KD; Elfiky, A; Hayes, JH; Kantoff, PW; Nakabayashi, M; Oh, WK; Sims, DM; Taplin, ME; Weckstein, D; Werner, L1
de Bono, JS; de Wit, R; Ebbinghaus, SW; Heath, KH; Hudes, GR; Li, X; Meulenbeld, HJ; Tagawa, ST; Whang, YE; Zandvliet, AS1
Beggs, RE; Bose, S; Crapuchettes, ME; D'Abronzo, LS; deVere White, RW; Durbin-Johnson, BP; Ghosh, PM; Melgoza, FU; Mudryj, M; Siddiqui, S; Tepper, CG; Vinall, RL1

Reviews

1 review(s) available for bicalutamide and sirolimus

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

2 trial(s) available for bicalutamide and sirolimus

ArticleYear
Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer.
    BJU international, 2012, Volume: 110, Issue:11

    Topics: Adenocarcinoma; Aged; Androgen Receptor Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Everolimus; Humans; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Sirolimus; Tosyl Compounds; Treatment Outcome

2012
Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC).
    Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:4

    Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Interactions; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Nitriles; Orchiectomy; Prospective Studies; Prostatic Neoplasms; Sirolimus; TOR Serine-Threonine Kinases; Tosyl Compounds

2013

Other Studies

7 other study(ies) available for bicalutamide and sirolimus

ArticleYear
Identifying off-target effects and hidden phenotypes of drugs in human cells.
    Nature chemical biology, 2006, Volume: 2, Issue:6

    Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship

2006
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
    Endocrine-related cancer, 2005, Volume: 12, Issue:1

    Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Antibiotics, Antineoplastic; Cell Proliferation; Enzyme Inhibitors; Humans; Ki-67 Antigen; Male; Mitogen-Activated Protein Kinases; Neoplasms, Hormone-Dependent; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Prostatic Hyperplasia; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Protein Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptors, Androgen; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tosyl Compounds; Tumor Cells, Cultured

2005
Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR.
    British journal of cancer, 2010, Sep-28, Volume: 103, Issue:7

    Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androstadienes; Anilides; Animals; Benzimidazoles; Castration; Cell Line, Tumor; Disease Progression; Drug Therapy, Combination; Everolimus; Intracellular Signaling Peptides and Proteins; Male; Mice; Mice, SCID; Neoplasms, Hormone-Dependent; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Receptor Cross-Talk; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tosyl Compounds; Xenograft Model Antitumor Assays

2010
Androgen receptor-mTOR crosstalk is regulated by testosterone availability: implication for prostate cancer cell survival.
    Anticancer research, 2010, Volume: 30, Issue:10

    Topics: Androgen Antagonists; Anilides; Apoptosis; Cell Line, Tumor; Cell Survival; Down-Regulation; Gene Knockdown Techniques; Glucose; Humans; Male; Nitriles; Prostatic Neoplasms; Receptor Cross-Talk; Receptors, Androgen; RNA, Small Interfering; Sirolimus; Testosterone; TOR Serine-Threonine Kinases; Tosyl Compounds; Tuberous Sclerosis Complex 1 Protein; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins

2010
Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models.
    International journal of oncology, 2012, Volume: 41, Issue:2

    Topics: Androgen Receptor Antagonists; Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Male; Mice; Mice, Nude; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; PTEN Phosphohydrolase; Receptors, Androgen; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tosyl Compounds; Tumor Burden; Xenograft Model Antitumor Assays

2012
The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.
    Oncogene, 2017, 11-16, Volume: 36, Issue:46

    Topics: Anilides; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Eukaryotic Initiation Factor-4E; Everolimus; Humans; Intracellular Signaling Peptides and Proteins; Male; Mice, Nude; Nitriles; Phosphorylation; Prostatic Neoplasms, Castration-Resistant; Protein Serine-Threonine Kinases; Purines; Receptors, Androgen; Serine; Sirolimus; TOR Serine-Threonine Kinases; Tosyl Compounds; Xenograft Model Antitumor Assays

2017